A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue

Exclusion Criteria

• •Have known or suspected allergies or hypersensitivities to LY2605541, human insulin, sinistrin, related compounds or any components of the formulations
• •Are women who are pregnant or lactating
• •Have an abnormal blood pressure for the population as determined by the investigator
• •Have renal insufficiency or major renal disorders
• •Have proliferative retinopathy or maculopathy
• •Have lipodystrophy
• •Have any wound healing disorder or are prone to keloid or hypertrophic scar formation
• •Have results of screening prothrombin time (PT) and international normalized ratio (INR) tests that are significantly prolonged
• •Have a fasting triglycerides value \> 4.52 millimoles per liter (mmol/L) (400 milligrams/deciliter (mg/dL))
• •Are receiving chronic systemic or inhaled glucocorticoid or have received such therapy within the 4 weeks before dosing
• •Have a total daily insulin dose greater than 1.2 units per kilogram (U/kg)
• •Regular use or intended use of any over-the-counter or prescription medications or nutritional supplements that affect blood glucose or the body's sensitivity to insulin or that promote weight loss within 14 days prior to dosing
• •Regular use or intended use of non-selective beta blockers
• •Regular use or intended use of monoamine oxidase (MAO) inhibitors
• •Are currently participating in a weight loss program or plan to do so during the course of the study
• •Are unwilling to avoid excessive sun exposure, steam baths, saunas, and swimming during the study. Sun cream should be used during sun bathing for the 6-month period following the study
• •Are unwilling to avoid extensive consumption of food containing inulin during the study and in the 48-hour period leading up to the clamp